Completed PHASE4 INTERVENTIONAL 2-arm NCT04260594

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).

Sponsor: Jieming QU

Conditions 2019-nCoV

Interventions Arbidol basic treatment

Updated 6 times since 2020 Last updated: Sep 6, 2021 Started: Feb 8, 2020 Primary completion: Mar 12, 2020 Completion: Dec 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates 2019-nCoV and is currently completed. Jieming QU leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2021 — Oct 2021 [monthly]

Completed PHASE4

Status: Not Yet Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Mar 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jieming QU

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China